Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to give their consent and are able to follow all the requirements of the trial
• People aged between 18 and 75 years old (any gender)
• People whose cancer cells (in the bone marrow or blood) have a specific protein marker called CD19, confirmed by a specialised blood test
• People who have been diagnosed with B-cell lymphoma that has come back or stopped responding to treatment — including certain slow-growing types (such as follicular lymphoma or marginal zone lymphoma) or faster-growing types (such as diffuse large B-cell lymphoma and related types) — or people diagnosed with B-cell acute lymphoblastic leukaemia (B-ALL) that meets specific relapse or treatment-resistance conditions (confirm with trial site)
• People whose bone marrow test shows more than 5% of a certain type of abnormal early blood cell
• People who have not had a stem cell transplant in the 6 months before joining the trial
• People with B-cell lymphoma who have at least one area of disease that can be measured on a scan, meeting specific size requirements, and showing activity on a PET-CT scan
• People with an expected survival of more than 12 weeks
• People with a good general health and activity level, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work)
• People whose liver, kidney, heart, and lung function meet certain minimum levels as confirmed by blood and other tests
• People whose blood cell counts meet certain minimum levels without needing a recent transfusion
• People who have stopped certain medications (such as steroids, immune-suppressing drugs, anti-cancer drugs, or certain antibody treatments) within the required timeframes before the trial treatment is given (confirm with trial site)
• People who are able to use effective contraception throughout the study, and for up to 2 years after treatment, if there is any possibility of pregnancy

Who may not be able to join:

• People who have active cancer cells in the fluid around the brain or spinal cord, brain metastases, or active lymphoma or leukaemia affecting the central nervous system (brain and spinal cord)
• People with a history of certain active brain or nervous system conditions, such as seizures, stroke, dementia, cerebellar disease, or autoimmune diseases affecting the brain
• People who have taken part in another clinical trial within the past 30 days, or who are still within a required waiting period after a previous trial drug
• People who have previously received certain targeted treatments directed at the CD19 or CD3 proteins, unless specific conditions about their immune cell levels and tumour markers are met (confirm with trial site)
• People who have previously received any gene therapy or CAR-T cell therapy, unless specific conditions about remaining CAR-T cells and immune function are met (confirm with trial site)
• People who have had radiation therapy within 2 weeks before the planned treatment infusion
• People with active hepatitis B, hepatitis C, HIV, or syphilis
• People with a serious, uncontrolled infection (such as bacteria, virus, or fungus) at the time of treatment
• People who have had unstable chest pain (angina) or a heart attack within the 6 months before screening
• People who have or have had another type of cancer, except in certain limited situations such as fully treated skin cancers, cervical or breast cancer in remission for at least 3 years, or another cancer that has been fully removed and in complete remission for at least 5 years
• People with irregular heart rhythms that are not controlled with medication
• People taking blood-thinning medication by mouth within 1 week before the treatment infusion
• People with active autoimmune or inflammatory conditions affecting the nervous system, such as Guillain-Barré syndrome or motor neurone disease
• People who are pregnant, breastfeeding, or planning a pregnancy within 2 years after receiving the trial treatment; this also applies to male participants whose partner is planning a pregnancy within 2 years
• People who have any other medical condition or circumstance that the trial doctors believe makes participation unsuitable or unsafe
• People who the trial doctors believe are unlikely to follow the trial requirements reliably

Important: Always verify eligibility with the trial site directly before applying.